

Press release

November 24, 2021

Warrants of series TO2 were exercised to approximately 97.3 percent and ISR Holding AB receives approximately SEK 62.4 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

ISR Immune System Regulation Holding AB (publ) (“ISR” or the “Company”) announces today the outcome of the exercise of warrants of series TO2, which were issued during the second quarter of 2020. In total, 8 014 269 warrants of series TO2 were exercised, corresponding to approximately 97.3 percent of the total number of outstanding warrants of series TO2, for subscription of 8 014 269 shares at a subscription price of SEK 7.78 per share. ISR will receive approximately SEK 62.4 million before issue costs through the exercise of the warrants of series TO2.

Background

The subscription period for exercise of the warrants of series TO2 took place from November 9, 2021, up to and including November 23, 2021. The subscription price per share for exercising the warrants of series TO2 was set to SEK 7.78.

Interim shares

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO2, the number of shares in ISR increases by 8 014 269 shares, from 60 994 682 shares to a total of 69 008 951 shares. The share capital will increase by approximately SEK 400 713, from approximately SEK 3 049 734 to approximately SEK 3 450 448.

For existing shareholders who did not exercise any warrants of series TO2, the dilution amounts to approximately 11.6 percent based on the number of shares following exercise of the warrants of series TO2.

Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal adviser to ISR regarding the warrants.

For further information, please contact:

Ola Winqvist
CEO, ISR Immune System Regulation Holding AB
Phone: +46 (0)70 5427939
Email: ola.winqvist@israb.se

About ISR Immune System Regulation Holding AB

ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company’s Certified Adviser and can be reached on phone



Phone: +46 (0)8-463 80 00

Email: ca@mangold.se

www.israb.se

Aktien

Ticker: ISR

ISIN-kod: SE0008212195

This information is such that ISR Immune System Regulation Holding AB (publ) is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the specified Company's contact person 2021-11-24

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered securities have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the EU "**Target Market Assessment**"). Solely for the purposes of each manufacturer's product approval process in the United Kingdom, the target market assessment in respect of the securities in the Company has led to the conclusion that: (i) the target market for such shares is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("**UK MiFIR**"); and (ii) all channels for distribution of such shares to eligible counterparties and professional clients are appropriate (the "**UK Target Market Assessment**" and, together with the EU Target Market Assessment, the "**Target Market Assessment**"). *Notwithstanding the Target Market Assessment, Distributors should note that: the price of ISR's shares or warrants may decline and investors could lose all or part of their investment; ISR's shares or warrants offer no guaranteed income and no capital protection; and an investment in ISR's shares or warrants is compatible only with investors*



who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the issuance of the Warrants.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares or warrants of ISR.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares and warrants in ISR and determining appropriate distribution channels.